Investor & Media Home
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
Learn more about our pipeline here.
Recent News
Feb 28, 2023
Feb 26, 2023
Feb 16, 2023
FRONT >> News > View All
View All Press Releases
Events & Presentations
Feb 26, 2023 at 5:00 PM EST
Feb 15, 2023 at 9:20 AM EST
Dec 6, 2022 at 8:00 AM EST
FRONT > Events - View All
View All Events
Corporate Presentation
More information is coming soon.
FRONT >> Presentations > View All
View Here Presentations